Key terms
About CLDX
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CLDX news
Apr 17
10:05am ET
Celldex’s Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation
Apr 17
8:18am ET
Celldex announces completion of enrollment in Phase 2 study of barzolvolimab
Apr 03
6:49am ET
Jasper Therapeutics initiated with an Outperform at Evercore ISI
Mar 21
10:46am ET
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
Mar 01
12:57am ET
Celldex Gains Buy Rating Amid Strong Barzolvolimab Phase 2 Results and Promising Clinical Timelines
Feb 29
9:45pm ET
Celldex 8.52M share Secondary priced at $47.00
Feb 28
5:24pm ET
Celldex announces $250M offering of common stock
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
11:40pm ET
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH)
Feb 27
8:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Revolution Medicines (RVMD)
Feb 27
7:51am ET
Celldex price target raised to $90 from $72 at Guggenheim
Feb 27
1:04am ET
Celldex Therapeutics’ New Regulation Risk – A Cause for Worry?
Feb 26
7:55am ET
Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)
Feb 26
7:36am ET
TD Cowen Keeps Their Buy Rating on Celldex (CLDX)
Feb 26
7:07am ET
Celldex expects cash to fund operations into 2026
Feb 26
7:06am ET
Celldex reports Q4 EPS (83c), consensus (74c)
Feb 26
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Abbott Labs (ABT) and Morphic Holding (MORF)
Feb 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), Legend Biotech (LEGN) and Celldex (CLDX)
Feb 25
6:32am ET
Celldex presents 12-week results from Barzolvolimab Phase 2 study in CSU
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 20
5:26am ET
TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels
Feb 07
8:36am ET
Buy Rating Affirmed for Celldex Amid Promising Barzovolimab Data for Chronic Spontaneous Urticaria
Feb 07
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 05
8:20am ET
Celldex announces upcoming presentation of barzolvolimab Phase 2 results
Jan 31
5:49am ET
Analyst Maintains Hold Rating on Celldex Amid Anticipated Phase 2 Results and Safety Considerations
No recent press releases are available for CLDX
CLDX Financials
Key terms
Ad Feedback
CLDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CLDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range